What newer oral disease‑modifying therapies are available for an adult with relapsing‑remitting multiple sclerosis, and what are their initiation protocols and monitoring requirements?

Newer Oral Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis

The currently available oral DMTs for adults with RRMS include fingolimod, dimethyl fumarate, diroximel fumarate, teriflunomide, cladribine tablets, siponimod, ozanimod, and ponesimod, with varying efficacy profiles and monitoring requirements based on their mechanisms of action. 1, 2

Available Oral DMTs and Their Mechanisms

First-Line (Moderate Efficacy) Agents

Dimethyl Fumarate (DMF) and Diroximel Fumarate (DRF)

• Mechanism: Immunomodulatory and cytoprotective functions 1
• Efficacy: Reduces annualized relapse rate (ARR) by approximately 50-60%, with most patients experiencing no relapses during treatment 3
• DRF advantage: Bioequivalent to DMF but with significantly lower GI adverse events (< 2% discontinuation due to GI issues) 3, 4
• Initiation: Can be started immediately in treatment-naïve patients
• Monitoring:
  • Baseline complete blood count (CBC) and liver function tests (LFTs)
  • CBC every 3-6 months to monitor for lymphopenia
  • Annual LFTs
  • MRI at baseline and annually 4

Teriflunomide

• Mechanism: Inhibits dihydroorotate dehydrogenase, blocking lymphocyte proliferation 1
• Efficacy: Modest ARR reduction (somewhat less than fingolimod, DMF, and cladribine) 2
• Initiation: 14 mg daily (no titration required)
• Monitoring:
  • Baseline LFTs, CBC, tuberculosis screening, pregnancy test
  • Monthly LFTs for first 6 months, then every 6-8 weeks
  • Blood pressure monitoring
  • Strict contraception required (teratogenic)

High-Efficacy Agents

Fingolimod

• Mechanism: Sphingosine-1-phosphate (S1P) receptor modulator causing lymphocyte sequestration 1
• Efficacy: Up to 60% reduction in ARR 1; comparable to cladribine and DMF 2
• Initiation Protocol:
  • First-dose observation required (6 hours minimum) due to bradycardia risk
  • Baseline ECG, ophthalmologic exam, varicella zoster virus (VZV) serology
  • Cardiac monitoring during first dose
• Monitoring:
  • Ophthalmologic exams at 3-4 months and annually (macular edema risk)
  • CBC every 3 months (lymphopenia)
  • LFTs every 3 months
  • VZV vaccination if seronegative (wait 1 month before starting)
  • MRI annually

Cladribine Tablets

• Mechanism: Targeted lymphocyte depletion in peripheral and central nervous system 5
• Efficacy: Comparable to highest-efficacy therapies; reduces ARR by 87.5-93% in real-world studies 6; achieves NEDA-3 in 87.5% of patients 6
• Unique advantage: Short treatment courses over 2 years only, reducing treatment burden 5
• Initiation Protocol:
  • Two treatment courses: Year 1 (weeks 1 and 5) and Year 2 (weeks 1 and 5)
  • Cumulative dose: 3.5 mg/kg over 2 years
  • Baseline lymphocyte count must be normal
• Monitoring:
  • Baseline: CBC with differential, LFTs, serum creatinine, tuberculosis screening, HIV test, hepatitis B/C screening, pregnancy test, VZV serology
  • CBC with differential: before each treatment course, at 2 and 6 months after each course
  • Active tuberculosis, HIV, or hepatitis B are contraindications
  • Lymphocyte count must be ≥ 800 cells/mm³ before initiating treatment
  • MRI annually 5

Siponimod, Ozanimod, Ponesimod (Newer S1P Modulators)

• Mechanism: More selective S1P receptor modulation than fingolimod 1
• Efficacy: Comparable to fingolimod for ARR reduction 2, 7
• Initiation: Titration required (unlike fingolimod); first-dose observation may be required depending on cardiac history
• Monitoring: Similar to fingolimod but potentially fewer cardiac effects due to receptor selectivity

Treatment Selection Algorithm

For treatment-naïve patients with highly active RRMS:

• Consider high-efficacy DMTs first (cladribine, ocrelizumab, alemtuzumab) as they provide substantial disease suppression (87-93% ARR reduction) when initiated early 6
• Cladribine tablets offer unique advantage: Only 2 years of treatment required, minimal monitoring visits, and efficacy comparable to continuous high-efficacy therapies 5, 6

For patients requiring moderate efficacy with better tolerability:

• Diroximel fumarate preferred over dimethyl fumarate: Bioequivalent efficacy but significantly lower GI adverse events 3, 4

For patients with high disease activity or sub-optimal response to platform therapies:

• Cladribine tablets demonstrate comparable efficacy to ofatumumab for disability progression and ocrelizumab for relapse reduction 7

Critical Monitoring Considerations

Enhanced Pharmacovigilance When Switching Therapies

When switching from natalizumab to oral DMTs (fingolimod, dimethyl fumarate, cladribine):

• Enhanced MRI surveillance every 3-4 months for up to 12 months due to "carry-over opportunistic infection" risk 8
• Brain MRI at time of natalizumab discontinuation and after new treatment initiation 8
• Use FLAIR, T2-weighted, and diffusion-weighted imaging protocols 8

Progressive Multifocal Leukoencephalopathy (PML) Risk Stratification

For patients on fingolimod or dimethyl fumarate with prolonged lymphopenia:

• Increased PML risk with lymphocyte counts < 500 cells/mm³ for > 6 months
• Consider switching therapy if persistent severe lymphopenia occurs
• MRI surveillance should include diffusion-weighted imaging 9

Common Pitfalls to Avoid

1. Failing to perform first-dose cardiac monitoring with fingolimod: Bradycardia can be severe; 6-hour observation is mandatory
2. Starting cladribine with abnormal lymphocyte counts: Baseline lymphopenia is a contraindication
3. Inadequate contraception counseling with teriflunomide: Highly teratogenic; requires accelerated elimination protocol if pregnancy desired
4. Missing ophthalmologic monitoring with fingolimod: Macular edema occurs in 0.5-1% of patients, typically at 3-4 months
5. Insufficient lymphocyte monitoring with all oral DMTs: Severe prolonged lymphopenia increases infection risk, particularly PML
6. Not screening for latent infections before cladribine: Tuberculosis, hepatitis B/C, HIV, and VZV status must be established

Long-Term Efficacy Considerations

Sustained benefit with continued treatment: Fingolimod and dimethyl fumarate show progressively lower ARR with continuing treatment over time 2. Cladribine provides durable efficacy beyond the 2-year treatment period, with NEDA-3 maintained at 4 years in 87.5% of patients 6.